Xenon Pharmaceuticals vs Zenas BioPharma
Zenas BioPharma reported revenue of $10 million in fiscal 2025, 1.3 times Xenon Pharmaceuticals' $8 million in fiscal 2025. Xenon Pharmaceuticals had an operating margin of -4974.3%, against -3830.6% at Zenas BioPharma. Free cash flow was −$280 million at Xenon Pharmaceuticals and −$172 million at Zenas BioPharma.
Side by side
| Xenon Pharmaceuticals | Zenas BioPharma | |
|---|---|---|
| Latest fiscal year | FY2025, Dec 31, 2025 | FY2025, Dec 31, 2025 |
| Revenue | $8M | $10M |
| Revenue growth | — | 100.0% |
| Revenue growth a year, last 5 years | −25.3% | — |
| Gross margin | — | — |
| Operating margin | −4,974.3% | −3,830.6% |
| Net margin | −4,612.1% | −3,777.4% |
| Free cash flow | −$280M | −$172M |
| Free cash flow margin | −3,732.2% | −1,723.5% |
| Return on capital | — | — |
| Net debt to EBITDA | — | — |
| Dividends and buybacks | $0M | $0M |
| Change in diluted share count | 1.7% | 238.9% |
| Last close | $40.48 | $28.01 |
| P/E at the last close | — | — |
| Insider trades, last 12 months | sold $22.0 million | — |
| Piotroski F-score | — | — |
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.
Ten years
Revenue
US$ billions, fiscal years
Xenon PharmaceuticalsZenas BioPharma
Operating margin
Percent of revenue
Xenon PharmaceuticalsZenas BioPharma
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
Xenon PharmaceuticalsZenas BioPharma
Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the Xenon Pharmaceuticals and Zenas BioPharma pages.